Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are approved treatments for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR mutations. The EGFR C797S mutation is one of the known acquired-resistance mutations to the latest third-generation TKIs. At pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Kuo-Yen, Wang, Tong-Hong, Chen, Chin-Chuan, Leu, Yann-Lii, Li, Hsin-Jung, Jhong, Cai-Ling, Chen, Chi-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470952/
https://www.ncbi.nlm.nih.gov/pubmed/34572484
http://dx.doi.org/10.3390/biom11091271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470952/
https://www.ncbi.nlm.nih.gov/pubmed/34572484
http://dx.doi.org/10.3390/biom11091271

Ejemplares similares